164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy

D Lorusso; I Vergote; A Oaknin; KS Tewari; AC De Melo; HS Kim; YM Kim; A Lisyanskaya; F Damian; CL Chang; D Rischin; S Takahashi; D Ramone; J Pikiel; EM Guerra Alía; J LI; S Jamil; M Mathias; MG Fury; BJ Monk

doi:10.1136/ijgc-2021-ESGO.14

Article info

Cervical cancer

164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy

Free

Authors

D Lorusso Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Italy PubMed articles Google scholar articles
I Vergote University Hospitals, Leuven, KU Leuven, Leuven, Belgium PubMed articles Google scholar articles
A Oaknin Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articles Google scholar articles
KS Tewari University of California, Irvine, Irvine, USA PubMed articles Google scholar articles
AC De Melo Brazilian National Cancer Institute, Rio de Janeiro, Brazil PubMed articles Google scholar articles
HS Kim Seoul National University College of Medicine, Seoul, Korea, Rep. of South PubMed articles Google scholar articles
YM Kim Asan Medical Center, University of Ulsan, Seoul, Korea, Rep. of South PubMed articles Google scholar articles
A Lisyanskaya St. Petersburg State Budgetary Institution of Healthcare, St. Petersburg, Russian Federation PubMed articles Google scholar articles
F Damian Hospital Sao Lucas PUCRS, Porto Alegre, Brazil PubMed articles Google scholar articles
CL Chang MacKay Memorial Hospital, Taipei, Taiwan PubMed articles Google scholar articles
D Rischin Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia PubMed articles Google scholar articles
S Takahashi The Cancer Institute Hospital of JFCR, Tokyo, Japan PubMed articles Google scholar articles
D Ramone Barretos Cancer Hospital (Pio XII Foundation), Barretos, Brazil PubMed articles Google scholar articles
J Pikiel Szpitale Pomorskie, Gdynia, Poland PubMed articles Google scholar articles
EM Guerra Alía Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain PubMed articles Google scholar articles
J LI Regeneron Pharmaceuticals, Inc., Tarrytown, USA PubMed articles Google scholar articles
S Jamil Regeneron Pharmaceuticals, Inc., Tarrytown, USA PubMed articles Google scholar articles
M Mathias Regeneron Pharmaceuticals, Inc., Tarrytown, USA PubMed articles Google scholar articles
MG Fury Regeneron Pharmaceuticals, Inc., Tarrytown, USA PubMed articles Google scholar articles
BJ Monk Arizona Oncology (US Oncology Network) University of Arizona, Creighton University, Phoenix, USA PubMed articles Google scholar articles

Citation

Lorusso D, Vergote I, Oaknin A, et al

164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy

International Journal of Gynecologic Cancer 2021;31:A10-A11.

Publication history

First published October 12, 2021.

Online issue publication

January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password